PADI2 and liver cancer: The suppression of PAD2 via anti-PAD2 siRNA treatment significantly increases the proliferation and migration of MKN-45 human gastric cancer cells and attenuates the apoptosis of these cells, but the decreased effects are observed in Bel-7402 liver cancer cells [11].